Table 3.

Univariate and multivariate analyses for prognostic factors of OS

Characteristics	Univariate analysis		Multivariate analysis
	HR (95% CI)	P	HR (95% CI)	P
Gender
Male (Ref)
Female	1.83 (0.43–7.75)	0.414
Age, years (continuous)	1.02 (0.97–1.07)	0.481
Functionality
Nonfunctional (Ref)
Functional	0.03 (0.00–21.2)	0.292
Tumor location
Head/neck (Ref)
Body/tail	2.66 (0.54–13.2)	0.232
Multiple parts	–	0.991
Tumor size, cm (continuous)	1.25 (1.09–1.44)	0.002	1.26 (1.06–1.49)	0.008
Tumor focality
Single (Ref)
Multiple	–	0.700
Necrosis
No (Ref)
Yes	4.15 (0.48–35.5)	0.194
Nerve invasion
No (Ref)
Yes	11.4 (2.74–47.3)	0.001	14.5 (2.93–72.1)	0.001
Vascular invasion
No (Ref)
Yes	4.24 (1.00–17.9)	0.050
Lymph node metastases
No (Ref)
Yes	3.96 (0.79–19.8)	0.094
WHO grade
G1 (Ref)
G2	6.62 (0.77–57.0)	0.085		NS
G3	31.3 (2.54–386)	0.007		NS
TNM stage
I (Ref)
II	–	0.944
III	–	0.940
IV	–	0.937
Synchronous liver metastases
No (Ref)
Yes	5.86 (0.67–51.2)	0.110
Platelet count, ×109/L (continuous)	1.00 (0.98–1.01)	0.663
Neutrophil count, ×109/L (continuous)	1.43 (0.79–2.58)	0.243
Lymphocyte count, ×109/L
≤1.4 (Ref)
>1.4	0.27 (0.06–1.12)	0.070
Monocyte count, ×109/L (continuous)	14.4 (0.06–3264)	0.334
PLR (continuous)	1.01 (0.99–1.02)	0.573
NLR
≤1.9 (Ref)
>1.9	5.76 (1.16–28.6)	0.032		NS
LMR
≤5.0 (Ref)
>5.0	0.57 (0.13–2.38)	0.566
SII index (continuous)	1.00 (1.00–1.00)	0.273

HR, hazard ratio; LMR, lymphocyte-to-monocyte ratio; NLR, neutrophil-to-lymphocyte ratio; NS, not significant; OS, overall survival; PLR, platelet-to-lymphocyte ratio; Ref, reference; SII, systemic immune-inflammation; WHO, World Health Organization.